Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.
Hyperphosphataemia is a usual accompaniment of end stage renal disease and dialysis, in the absence of dietary phosphate restriction or supplemental phosphate binders. It is associated with renal osteodystrophy, metastatic calcification and increased mortality and morbidity. Despite dietary restriction and dialysis, most patients will require a phosphate-binding agent to treat this condition. However, phosphate control has not significantly improved over the last two decades, mainly because of the lack of an ideal oral phosphate-binding agent. Aluminium- and calcium-based agents are associated with major side effects, despite their undoubted efficacy. Although sevel-amer hydrochloride represents a step forward in the management of hyperphosphataemia, it is not an ideal phosphate binder due to its cost and tablet burden. Lanthanum carbonate is the most recent non-calcium, non-aluminium, phosphate-binding agent. It is effective and well-tolerated, and no negative effects on bone histology have been observed.
Albaaj
Fouad
F
Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, UK.
Hutchison
Alastair J
AJ
D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D007811:Lanthanum / Q000097:blood / Q000627:therapeutic use*; D010710:Phosphates / Q000097:blood; D010760:Phosphorus Metabolism Disorders / Q000097:blood / Q000188:drug therapy*; D006435:Renal Dialysis / Q000706:statistics & numerical data*; D051437:Renal Insufficiency / Q000097:blood / Q000188:drug therapy*
D010710:Phosphates; C119467:lanthanum carbonate; D007811:Lanthanum